Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...
news.bloomberglaw1d
Insider Defeats 'Pen Register' Suit Over IP-Address Disclosure
Disclosure of IP addresses not a concrete injury for standing Pen-register law didn’t codify substantive privacy right Online news service Insider Inc. defeated a proposed class action alleging it ...
Compoundsemiconductor.net3d
Frontgrade qualifies Class L GaN DC-DC and EMI filter
Frontgrade Technologies, a US provider of electronics for aerospace and defence, has qualified to Class L standards its ...